Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 999.02 |
| Open | 1,003.31 |
| Bid | 1,014.47 x 100 |
| Ask | 1,016.23 x 100 |
| Day's range | 996.28 - 1,017.74 |
| 52-week range | 769.19 - 1,211.20 |
| Volume | |
| Avg. volume | 536,848 |
| Market cap | 111.962B |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | 26.88 |
| EPS (TTM) | 37.78 |
| Earnings date | 31 Oct 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,172.49 |
ZacksKodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
ZacksRegeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Regeneron (REGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ZacksRegeneron Gains 13.5% Year to date: How to Play the Stock?
REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.
© 2024 Yahoo. All rights reserved.